Viewing Study NCT00109655



Ignite Creation Date: 2024-05-05 @ 11:41 AM
Last Modification Date: 2024-10-26 @ 9:11 AM
Study NCT ID: NCT00109655
Status: UNKNOWN
Last Update Posted: 2008-10-03
First Post: 2005-05-02

Brief Title: Dose-Escalation Study of CG0070 for Bladder Cancer After BCG Bacillus Calmette-Guerin Failure
Sponsor: Cell Genesys
Organization: Cell Genesys

Study Overview

Official Title: A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure
Status: UNKNOWN
Status Verified Date: 2008-10
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The main purpose of this research study is to evaluate the safety and dosing of CG0070
Detailed Description: Cohorts of three to six patients will be assigned to receive intravesical into the bladder administration of CG0070 either Weekly or Every 4 Weeks for up to a total of 6 doses

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None